learn SCUBE3
a signaling molecule from dermal papilla cells being actively researched
Search
forLearn
5 / 801 resultslearn KY19382
compound that activates Wnt/β-catenin to promote hair regrowth and create new hair follicles
learn octapeptide-2
learn sh-Polypeptide-7
learn Marilex-M
Research
5 / 505 resultsresearch Epidermal Dysplasia and Abnormal Hair Follicles in Transgenic Mice Overexpressing Homeobox Gene MSX-2
Overexpressing the MSX-2 gene in mice causes skin and hair growth issues.
research 026 Altered Skin Wound Healing in Homeobox Gene Msx-2 Knockout Mice
Msx-2 gene removal speeds up skin wound healing in mice.
research Regulation of feather follicle development and Msx2 gene SNP degradation in Hungarian white goose
The Msx2 gene affects feather development in Hungarian white geese and a specific gene variation could indicate feather quality.
research Msx2 Supports Epidermal Competency during Wound-Induced Hair Follicle Neogenesis
The gene Msx2 is crucial for hair follicle regeneration during wound healing.
research Msx2 deficiency in mice causes pleiotropic defects in bone growth and ectodermal organ formation
Msx2 deficiency in mice leads to bone growth and organ development problems.
Community Join
5 / 1000+ resultscommunity MCL1 does anyone knows anthying about it
MCL-1 protein may help maintain hair follicles in the growth phase and prevent miniaturization. There is interest in experimental treatments like exosomes, peptides, or stem cell serums to upregulate MCL-1 for hair loss, especially for those not using minoxidil or finasteride.
community Expectations control for SCUBE3
SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.
community KX-826 Phase II Results Just Dropped (Male AGA) – Key Takeaways
KX-826 Phase II results show that a 0.5% concentration performs better than 1% for treating male pattern baldness. Concerns about receptor upregulation from long-term DHT antagonism were mentioned.
community Kintor Pharma Announced Successful Dosing of the First Patient for Acne Vulgaris Phase II Clinical Trial of KX-826
Kintor Pharma successfully dosed the first patient in a Phase II trial for KX-826 for acne vulgaris. Users are more interested in results for male pattern baldness (MPB).
community KX-826 , a small change in the pipeline
KX-826 is undergoing trials for hair loss treatment, showing similar effectiveness between 0.5% and 1.0% dosages, with mild side effects compared to finasteride. Users discuss combining KX-826 with other treatments like minoxidil and clascoterone for better results.